<DOC>
	<DOCNO>NCT00193609</DOCNO>
	<brief_summary>In phase II trial , evaluate feasibility efficacy oxaliplatin/capecitabine combination patient one previous chemotherapy regimen treatment carcinoma unknown primary site . Patients relapse previous response treatment eligible , well refractory first-line therapy .</brief_summary>
	<brief_title>Oxaliplatin Capecitabine Treatment Relapsed/Refractory Carcinoma Unknown Primary Site</brief_title>
	<detailed_description>All patient receive treatment oxaliplatin 130mg/m2 , give intravenously day 1 21 day cycle . Capecitabine 1000mg/m2 PO BID administer day 1-14 cycle .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>To include study , must meet following criterion : Histologically confirm carcinoma unknown primary site Progressive disease treatment one previous chemotherapy regimen . Treatment one previous immunotherapy biotherapy regimen . No previous treatment oxaliplatin , capecitabine , 5FU . Previous treatment platinum agent Patients must measurable evaluable disease ECOG Performance Status 2 Adequate bone marrow , liver kidney function Understand nature study give write informed consent . You participate study follow apply : Age &lt; 18 year History treatment invasive malignancy within last 5 year Coexistent medical illness Clinically significant cardiac disease Preexisting peripheral neuropathy &gt; grade 1 Lack physical integrity upper gastrointestinal tract Preexisting uncontrolled coagulopathy Women pregnant lactate Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Neoplasms , Unknown Primary</keyword>
</DOC>